Shukra Pharmaceuticals has signed a non-binding Memorandum of Understanding (MoU) with US-based Borns Medical Robotics to introduce advanced AI-enabled surgical robotic systems in India and select South Asian markets. Executed through Shukra’s subsidiary Shukra Robotics, the collaboration focuses on commercializing high-precision platforms for minimally invasive soft-tissue surgeries, pending regulatory approvals.
Glimpse:
Announced on January 5, 2026, the MoU covers India, Nepal, Bangladesh, Sri Lanka, Maldives, and Bhutan. It leverages Shukra’s regulatory expertise and distribution network with Borns’ cutting-edge robotic technology integrating AI for standardized workflows, reduced variability, and enhanced outcomes. Future steps include definitive agreements, technology transfer, clinician training, and scalable deployment to expand access to robot-assisted procedures.
Shukra Pharmaceuticals Ltd has entered a strategic collaboration with Borns Medical Robotics, a globally recognized US player in surgical robotics, through a non-binding Memorandum of Understanding (MoU) signed on January 5, 2026. This partnership aims to introduce and commercialize AI-powered surgical robotic systems across India and neighboring South Asian countries, marking Shukra’s diversification into medical robotics.
The initiative will be driven by Shukra Robotics, a wholly owned subsidiary, utilizing Shukra Pharmaceuticals’ established regulatory capabilities, healthcare market presence, and extensive distribution channels. Borns Medical Robotics contributes its expertise in high-precision, stability-driven platforms tailored for complex soft-tissue surgeries.
Core focus areas include:
Expanding access to robot-assisted minimally invasive surgeries.
Integrating artificial intelligence with digital surgery workflows for consistent procedural pathways and reduced outcome variability.
Strengthening infrastructure via technology transfer, comprehensive clinician training programs, and scalable deployment models.
The geographic scope encompasses India, Nepal, Bangladesh, Sri Lanka, Maldives, and Bhutan subject to applicable regulatory approvals and clearances. The MoU sets a framework for future definitive agreements based on mutually agreed commercial terms.
This move reflects growing adoption of AI-enhanced robotics globally, where systems support surgeons with superior visualization, tremor-free precision, and data-driven insights particularly valuable in oncology, urology, gynecology, and general surgery.
Shukra Pharmaceuticals, traditionally a player in formulations and APIs, views this as a long-term growth avenue in high-tech healthcare delivery. Borns Medical Robotics, known for innovative minimally invasive solutions, gains a strategic entry into one of the world’s fastest-growing medtech markets.
“This strategic collaboration reflects our intent to bring global-standard AI-powered robotic surgery to India and South Asia, enhancing precision and accessibility.”
By
HB Team
